1. Will other drugmakers end up with deals like Endo’s $10M opioid settlement? — AstraZeneca Imfinzi combo fails advanced lung cancer study — FDA says they were “lucky” with Novartis data manipulation controversy — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

CRISPR/Cas9 – Market Players Snapshot ?

Discussion in 'Amgen IT' started by naresh, Feb 25, 2016 at 7:24 AM.

  1. naresh

    naresh new user

    Joined:
    Dec 8, 2015
    Messages:
    4
    Likes Received:
    0
    Despite the ongoing patent war, a lot of startups and industry heavyweights have jumped on to the CRISPR/Cas9 bandwagon, seeing its potential in creating cures for various diseases such as AIDS, Cancer, and many more.Read here!